Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.855 EUR | -4.52% | +3.82% | +4.96% |
Mar. 15 | Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development | MT |
2023 | Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results | MT |
Sales 2021 | 1.93M 2.07M | Sales 2022 | 1.9M 2.03M | Capitalization | 5.1M 5.47M |
---|---|---|---|---|---|
Net income 2021 | 1M 1.07M | Net income 2022 | - 0 | EV / Sales 2021 | 3.77 x |
Net cash position 2021 | 486K 521K | Net cash position 2022 | 421K 451K | EV / Sales 2022 | 2.47 x |
P/E ratio 2021 |
4.78
x | P/E ratio 2022 |
14
x | Employees | 7 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.51% |
1 day | +0.50% | ||
1 week | +6.79% | ||
Current month | +9.12% | ||
1 month | +3.10% | ||
3 months | +5.28% | ||
6 months | -2.29% | ||
Current year | +9.93% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 94-12-31 | |
Patrice Coffe
DFI | Director of Finance/CFO | 55 | 08-06-30 |
Chief Tech/Sci/R&D Officer | - | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jean-Luc Rivière
BRD | Director/Board Member | - | 12-06-25 |
Chief Executive Officer | 50 | 94-12-31 | |
Patrice Coffe
DFI | Director of Finance/CFO | 55 | 08-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 2.855 | -4.52% | 11 982 |
24-04-24 | 2.99 | +0.50% | 27,701 |
24-04-23 | 2.975 | +0.85% | 23,157 |
24-04-22 | 2.95 | +1.72% | 8,884 |
24-04-19 | 2.9 | +5.45% | 41,321 |
Real-time Euronext Paris, April 24, 2024 at 11:35 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+9.93% | 10.59M | |
-10.65% | 197B | |
+1.54% | 166B | |
+12.56% | 169B | |
+5.85% | 101B | |
+6.27% | 76.87B | |
+16.57% | 71.98B | |
-6.96% | 71.09B | |
-22.12% | 51.76B | |
+2.33% | 48.08B |
- Stock Market
- Equities
- ALKLA Stock